Does amifostine have a role in chemoradiation treatment?
- 1 June 2003
- journal article
- Published by Elsevier in The Lancet Oncology
- Vol. 4 (6) , 378-380
- https://doi.org/10.1016/s1470-2045(03)01132-x
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Design and analysis of non‐inferiority mortality trials in oncologyStatistics in Medicine, 2002
- Has the outlook improved for amifostine as a clinical radioprotector?Radiotherapy and Oncology, 2000
- Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual dataThe Lancet, 2000
- Chemoradiotherapy of Locally Advanced Esophageal CancerJAMA, 1999
- Improved Treatment for Cervical Cancer — Concurrent Chemotherapy and RadiotherapyNew England Journal of Medicine, 1999
- Concurrent Cisplatin-Based Radiotherapy and Chemotherapy for Locally Advanced Cervical CancerNew England Journal of Medicine, 1999
- Pelvic Radiation with Concurrent Chemotherapy Compared with Pelvic and Para-Aortic Radiation for High-Risk Cervical CancerNew England Journal of Medicine, 1999
- Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer.Journal of Clinical Oncology, 1996
- Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group.Journal of Clinical Oncology, 1993
- Effective Surgical Adjuvant Therapy for High-Risk Rectal CarcinomaNew England Journal of Medicine, 1991